Multiple system atrophy: cellular and molecular pathology
- PMID: 11724918
- PMCID: PMC1187133
Multiple system atrophy: cellular and molecular pathology
Abstract
Multiple system atrophy is an adult onset neurodegenerative disease, featuring parkinsonism, ataxia, and autonomic failure, in any combination. The condition is relentlessly progressive and responds poorly to treatment. Death occurs on average six to seven years after the onset of symptoms. No familial cases of multiple system atrophy have been reported, and no environmental factors have been robustly implicated as aetiological factors. However, analytical epidemiological studies are hampered because the condition is relatively rare. The discovery of the glial cytoplasmic inclusion (GCI) in 1989 helped to define multiple system atrophy as a clinicopathological entity, and drew attention to the prominent, if not primary, role played by the oligodendrocyte in the pathogenesis of the condition. Subsequently, GCIs were shown to be positive for alpha-synuclein, with immunostaining for this protein indicating that white matter pathology was more widespread than had previously been recognised. The presence of alpha-synuclein in GCIs provides a link with Parkinson's disease, dementia with Lewy bodies, and neurodegeneration with brain iron accumulation, type 1 (or Hallervorden-Spatz syndrome), in which alpha-synuclein is also found within Lewy bodies. This has led to the term "synucleinopathy" to embrace this group of conditions. The GCIs of multiple system atrophy contain a range of other cytoskeletal proteins. It is unknown how fibrillogenesis occurs, and whether there is primary oligodendrocytic dysfunction, which then disrupts the neurone/axon as a consequence of the glial pathology, or whether the oligodendrocytic changes merely represent an epiphenomenon. Further research into this devastating condition is urgently needed to improve our understanding of the pathogenesis, and also to produce new treatment approaches.
Figures

Similar articles
-
The role of alpha-synuclein in the pathogenesis of multiple system atrophy.Acta Neuropathol. 2005 Feb;109(2):129-40. doi: 10.1007/s00401-004-0935-y. Epub 2005 Jan 22. Acta Neuropathol. 2005. PMID: 15666181 Review.
-
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.Ann Neurol. 1998 Sep;44(3):415-22. doi: 10.1002/ana.410440324. Ann Neurol. 1998. PMID: 9749615
-
Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10. Brain. 2010. PMID: 19903734
-
The pathogenesis of multiple system atrophy: past, present, and future.Mov Disord. 2000 Sep;15(5):784-8. doi: 10.1002/1531-8257(200009)15:5<784::aid-mds1004>3.0.co;2-p. Mov Disord. 2000. PMID: 11009180 Review.
-
Neuropathological spectrum of synucleinopathies.Mov Disord. 2003 Sep;18 Suppl 6:S2-12. doi: 10.1002/mds.10557. Mov Disord. 2003. PMID: 14502650 Review.
Cited by
-
alpha-Synuclein promotes the recruitment of tau to protein inclusions in oligodendroglial cells: effects of oxidative and proteolytic stress.J Mol Neurosci. 2009 Sep;39(1-2):226-34. doi: 10.1007/s12031-009-9190-y. Epub 2009 Mar 6. J Mol Neurosci. 2009. PMID: 19266322
-
Coenzyme Q10 Supplementation for the Reduction of Oxidative Stress: Clinical Implications in the Treatment of Chronic Diseases.Int J Mol Sci. 2020 Oct 23;21(21):7870. doi: 10.3390/ijms21217870. Int J Mol Sci. 2020. PMID: 33114148 Free PMC article. Review.
-
17-AAG induces cytoplasmic alpha-synuclein aggregate clearance by induction of autophagy.PLoS One. 2010 Jan 18;5(1):e8753. doi: 10.1371/journal.pone.0008753. PLoS One. 2010. PMID: 20090920 Free PMC article.
-
Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level.Neuroimage Clin. 2019;22:101720. doi: 10.1016/j.nicl.2019.101720. Epub 2019 Feb 13. Neuroimage Clin. 2019. PMID: 30785051 Free PMC article.
-
Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy.J Neurosci Res. 2009 Sep;87(12):2728-39. doi: 10.1002/jnr.22089. J Neurosci Res. 2009. PMID: 19405128 Free PMC article.
References
-
- Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771–5. - PubMed
-
- Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94–8. - PubMed
-
- Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy Drager syndrome). J Neurol Sci 1989;94:79–100. - PubMed
-
- Kato S, Nakamura H, Hirano A, et al. Argyrophilic ubiquitinated cytoplasmic inclusions of Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol 1991;82:488–93. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous